IXX Jornadas del Comité de Graduados de la Sociedad Argentina de Diabetes. Tema: “Diabetes y órganos no clásicos”. Mesa 1: Pulmón y diabetes mellitus
DOI:
https://doi.org/10.47196/diab.v57i1.678Palabras clave:
diabetes mellitus, enfermedad pulmonarResumen
Las alteraciones pulmonares en personas con diabetes mellitus (DM) son cada vez más frecuentes. Su fisiopatología es compleja y multifactorial. En la siguiente revisión se expondrán las principales características de la relación entre la DM y las enfermedades pulmonares.
Citas
I. Kolahlan S, Leiss V, Nürnberg B. Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord 2019;20:303-319.
II. Pitocco D, Fusso L, Conte EG, et al. The diabetic lung. A new target organ? Rev Diabet Stud 2012;9:23-35.
III. Kaparianos A, Argyropoulou E, Sampsonaset F, et al. Pulmonary complications in diabetes mellitus. Chronic Respiratory Disease 2008;5:101-108.
IV. Gumieniczek, A, Hopkala, H, Wojtowicz, Z, et al. Changes in antioxidant status of lung tissue in experimental diabetes in rabbits. Clin Biochem 2002;35:147-149.
V. Zheng H, Wu J, Jin Z, et al. Potential biochemical mechanisms of lung injury in diabetes. Aging and disease 2017;1:716.
VI. Indyk D, Bronowicka-Szydełko A, Gamian A, et al. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. Nature Scientific Report 2021;11:13264.
VII. Oczypok-Elizabeth A, Perkins-Timothy N, Oury-Tim D. All the “RAGE” in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatric Respiratory Reviews 2017;23:40-49.
VIII. Njeim R, Azar WS, Fares AH, et al. NETosis contributes to the pathogenesis of diabetes and its complication. Journal of Molecular Endocrinology 2020;65:4R65-R76.
IX. Chance WW, Rhee C, Yilmaz C, et al. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care 2008;31:1596-1601.
X. Visca P, Pignatti A, Spanevello E, Lucini E. Relationship between diabetes and respiratory diseases. Clinical and therapeutic aspects. Pharmacological Research 2018; 130:230-235.
XI. Talakatta G, Sarikhani M, Muhamed J, et al. Diabetes induces fbrotic changes in the lung through the activation of TGF-β signaling pathways. Nature Scientific Reports 2018; 8:11920.
XII. Rajasurya V, Gunasekaran K, Surani S. Interstitial lung disease and diabetes. World J Diabetes 2020;11(8):351-357.
XIII. López-Cano C, Lecube A, García-Ramírez M, et al. Serum surfactant protein D as a biomarker for measuring lung involvement in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2017;102(11):4109-4116.
XIV. Deng D, Yan N. GLUT, SGLT, and SWEET: structural and mechanistic investigations of the glucose transporters. Protein Sci 2016;25(3):546-558.
XV. Röhling M, et al. Impaired lung function in recent type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2018;126:584-589.
XVI. Schuyler MR, Niewoehner DE, Inkley SR, et al. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Respir Dis 1976;113(1):37-41.
XVII. Sandler M, Bunn AE, Stewart RI. Cross-section study of pulmonary function in patients with insulin-dependent diabetes mellitus. Am Rev Respir Dis 1987;135(1):223-9.
XVIII. Davis TM, Knuiman M, Kendall P, et al. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2000;50(2):153-9.
XIX. Davis WA, Knuiman M, Kendall P, et al. Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004;27(3):752-7.
XX. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: The Framingham Heart Study. Am J Respir Crit Care Med 2003;167:911-6.
XXI. Klein OL, Krishnan JA, Glick S, et al. Systematic review of the association between lung function and type 2 diabetes mellitus. Diabet Med 2010;27(9):977-87.
XXII. Van den Borst B, Gosker HR, Zeegers MP, et al. Pulmonary function in diabetes: a metaanalysis. Chest 2010;138(2):393-406.
XXIII. Díez-Manglano J, Asìn-Samper U. Pulmonary function tests in type 2 diabetes: a meta-analysis. ERJ Open Res 2021;7(1):00371-2020.
XXIV. Pitocco D, Fuso L, Conte EG, et al. The diabetic lung a new target organ? Rev Diabet Stud 2012;9(1):23-35.
XXV. Launois C, Barbe C, Bertin E, at al. The modified medical research council sacale for the assessmentof dyspnea in daily living in obesity: a pilot study. BMC Pulmonary Medicine 2012;12: 61.
XXVI. Khateeb J, Fuchs E, Khamaisi M. Diabetes and lung disease: an underestimated relationship. Rev Diabet Stud 2019;15:1-15.
XXVII. Wu TD. Diabetes and glycemic dysfunction in asthma. J Allergy ClinImmunol Pract 2020;8:3416-7.
XXVIII. Kolahian S, Leiss V, Nürnberg B. Diabetic lung disease: facto or fiction? Rev Endrocr Metab Disord 2019;20:303-319.
XXIX. Rogala B, Bożek A, Gluck J. Is there a relationship between asthma and diabetes? Journal of Asthma 2020;57(12):1332-1338.
XXX. Rasmussen SM, Brok J, Backer V, et al. Association between chronic obstructive pulmonary disease and type 2 diabetes: a systematic review and meta-Analysis. COPD: J Chronic Obst Pul Dis 2002;15:526-535.
XXXI. Gläser S, Krüger S, Merkel M, et al. Chronic obstructive pulmonary disease and diabetes mellitus. A systematic review of the literature. Respiration 2015;89:253-264.
XXXII. Ho TW, Huang CT, Ruan SY, et al. Diabetes mellitus in patients with chronic obstructive pulmonary disease. The impact on mortality. PLoS ONE 2017;12(4): e0175794.
XXXIII. Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovascular Diabetology 2020;11:132.
XXXIV. Pu X, Liu L, Feng B, et al. Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta‑analysis. Respir Res 2021;22:201.
XXXV. Lopardo GD, Fridman D, Raimondo E, et al. Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. BMJ Open 2018;8:e019439.
XXXVI. Falguera, et al. Etiology and outcome of community acquired pneumonia in patients with diabetes mellitus. Chest 2005;128:3233-3239.
XXXVII. Ramírez JA, et al. Treatment of community-acquired pneumonia in immunocompromised adults. A consensus statement regarding initial strategies. Chest 2020;158(5):1896-1911.
XXXVIII. Lepper PM, et al. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 2012;344: e3397.
XXXIX. Kornum JB, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia. Diabetes Care 2009;31:1541-1545.
XL. Kornum JB, et al. Type 2 diabetes and pneumonia outcomes. Diabetes Care 2007; 30:2251-2257.
XLI. Kyi M, et al. Increased hyperglycemia and hospital acquired infections following withdrawal of the RAPIDS early intervention model of diabetes care in medical and surgical inpatients. Diabetes Care 2021;44:e25-e26.
XLII. Gupta S, Koirala J, Khardori R, et al. Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin North Am 2007;21:617-3.
XLIII. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia 2020;12:11.
XLIV. Arias-Fernández L, et al. Differences between diabetic and non-diabetic patients with community-acquired pneumonia in primary care in Spain. BMC Infect Dis 2019; 19(1):973.
XLV. Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient service. Lancet Diabetes Endocrinol 2014;2:740-753.
XLVI. Van Crevel R, Critchley JA. The interaction of diabetes and tuberculosis: translating research to policy and practice. Tropical Medicine and Infectious Disease 2021;6(1):8.
XLVII. Lee MR, Huang YP, Kuo T, et al. Diabetes mellitus and latent tuberculosis infection. A systematic review and meta-analysis. Clin Infect Dis 2017;64:719-727.
XLVIII. Hensel RL, Kempker RR, Tapia J, et al. Increased risk of latent tuberculous infection among persons with pre-diabetes and diabetes mellitus. Int J. Tuberc Lung Dis 2016;20: 71-78.
XLIX. Lin Y, Harries AD, Kumar AM, et al. Tackling diabetes mellitus and tuberculosis: A new Union guide on the management of diabetes-tuberculosis. Int J Tuberc Lung Dis 2019; 23:771-772.
L. Awad SF, Critchley JA, Abu-Raddad LJ. Epidemiological impact of targeted interventions for people with diabetes mellitus on tuberculosis transmission in India: Modelling based predictions. Epidemics 2020;30:100381.
LI. Aung AT, Koo CY, Tam WW, et al. Sleep apnea and diabetes mellitus are independently associated with cardiovascular events and hospitalization for heart failure after coronary artery bypass grafting. Sci Rep 2020;10:21664.
LII. Schipper SBJ, Van Veen MM, Elders PJM, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia 2021; 64:2367-2377.
LIII. Visca D, Pignatti P, Spanevello A, Lucini E, La Rocca E. Relationship between diabetes and respiratory diseases. Clinical and therapeutic aspects, pharmacological research 2018;137:230-235.
LIV. Aung AT, Koo CY, Tam WW, et al. Sleep apnea and diabetes mellitus are independently associated with cardiovascular events and hospitalization for heart failure after coronary artery bypass grafting. Sci Rep 2020;10:21664.
LV. Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes. A state-of the-art review. Chest 2017;152(5):1070-1086.
LVI. Pamidi S, et al. Best practice & research clinica. Endocrinology & Metabolism 2010; 24:703-715.
LVII. Loffler KA, et al. Continuous positive airway pressure treatment, glycemia, and diabetes risk in obstructive sleep apnea and comorbid cardiovascular disease. Diabetes Care 2020;43:1859-1867.
LVIII. Song SO, et al. Metabolic consequences of obstructive sleep apnea especially pertaining to diabetes mellitus and insulin sensitivity. Diabetes Metab J 2019;43(2):144-155.
LIX. Schipper SBJ, Van Veen MM, Elders PJM, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia 2021;64(11):2367-2377.
LX. Hall GC, et al. Diabetes and the risk of lung cancer. Diabetes Care 2005;28:590-594.
LXI. Abudawood M. Diabetes and cancer: a comprehensive review. J Res Med Sci 2019; 24:94.
LXII. Giovannucci E, et al. Diabetes and cancer. A consensus report. Diabetes Care 2010; 33:1674-1685.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Diabetes
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
